A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Key facts

Sponsor

AbbVie

Principal Investigator

ABBVIE INC.

AbbVie

Intervention

Livmoniplimab(drug)

Enrollment

660 enrolled

Eligibility

18 years · All sexes

Timeline

2024 – 2030

Study locations (30)

• City of Hope /ID# 261468, Duarte, California, United States
• City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669, Irvine, California, United States
• UC Irvine /ID# 255673, Orange, California, United States
• The University of Chicago Medical Center /ID# 255674, Chicago, Illinois, United States
• Alliance for Multispecialty Research LLC Kansas City Oncology /ID# 256830, Merriam, Kansas, United States
• Norton Cancer Institute /ID# 260775, Louisville, Kentucky, United States
• Henry Ford Hospital /ID# 255803, Detroit, Michigan, United States
• Metro Minnesota Community Oncology Research Consortium (MMCORC) /ID# 256041, Saint Louis Park, Minnesota, United States
• Washington University-School of Medicine /ID# 255720, St Louis, Missouri, United States
• Texas Oncology - Abilene - Antilley Road /ID# 265820, Abilene, Texas, United States
• Texas Oncology - Dallas - Worth Street /ID# 265806, Dallas, Texas, United States
• Baylor Scott and White Research Institute /ID# 260853, Dallas, Texas, United States
• Oncology and Hematology Associates of Southwest Virginia /ID# 265834, Roanoke, Virginia, United States
• CHU Grenoble - Hopital Michallon /ID# 256627, La Tronche, Isere, France
• Institut Gustave Roussy /ID# 258460, Villejuif, Val-de-Marne, France
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

• ENROLLING BY INVITATIONPHASE2NCT07441369
  Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
  Fudan University
• RECRUITINGPHASE2NCT07175441
  Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma
  Riboscience, LLC.
• RECRUITINGPHASE2NCT07560488
  Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT07291076
  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
  Bristol-Myers Squibb
• RECRUITINGPHASE2NCT07010497
  A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma
  Asan Medical Center
• RECRUITINGPHASE1, PHASE2NCT07500220
  Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
  Beijing Biotech
• RECRUITINGPHASE2NCT07413354
  Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma
  Tongji Hospital
• RECRUITINGNANCT07365527
  Sonoporation and Tumor Microenvironment Response in Colorectal Liver Metastases
  Zealand University Hospital

See all trials for Adult hepatocellular carcinoma →